Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EPS (Weighted Average and Diluted) (2020 - 2025)

Keros Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.38 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 66.07% year-over-year to -$0.38; the TTM value through Dec 2025 reached $2.3, up 146.09%, while the annual FY2025 figure was $2.3, 146.0% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.38 in Q4 2025 per KROS's latest filing, down from -$0.18 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.62 in Q1 2025 to a low of -$1.41 in Q3 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.73, with a median of -$1.06 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 266.67% in 2022, then soared 399.17% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.3 in 2021, then plummeted by 266.67% to -$1.1 in 2022, then dropped by 21.82% to -$1.34 in 2023, then rose by 16.42% to -$1.12 in 2024, then surged by 66.07% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for KROS's EPS (Weighted Average and Diluted) are -$0.38 (Q4 2025), -$0.18 (Q3 2025), and -$0.76 (Q2 2025).